Innovative CGM PDT offers a hollow glucose sensor enabling single-needle weekly wear that integrates CGM and insulin infusion, presenting a compelling value proposition for patients seeking less painful, more convenient diabetes management.

Pediatric & Reluctant Patients The technology emphasis on reducing needle trauma and adhesive issues positions PDT as an appealing partner for clinics and payers targeting pediatric patients and adults with needle anxiety.

Integrated Delivery Products include a needle-free CGM Injection Port, CGM Infusion Set, and infusion cannula for tubeless pumps, offering bundled solutions for endocrinology practices and device manufacturers seeking integrated CGM/insulin delivery options.

Growth Opportunity With revenue in the low to mid six figures and a small team, PDT presents a scalable target for partnerships with larger medical device companies (e.g., pump makers) or distributors looking to expand CGM/infusion portfolios.

Strategic Partnerships Strong alignment with automated insulin delivery ecosystems suggests cooperation with major players in diabetes care for co-development, licensing, or channel partnerships to accelerate market adoption.